Status:
NOT_YET_RECRUITING
Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma
Lead Sponsor:
University of Cologne
Conditions:
Classical Hodgkin Lymphoma
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients w...
Eligibility Criteria
Inclusion
- Histologically proven first diagnosis of cHL
- Stage I-II without risk factors
- Large mediastinal mass
- Extranodal involvement
- Elevated erythrocyte sedimentation rate (ESR)
- Involvement of ≥ 3 nodal areas
Exclusion
- Central nervous system lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma,
- Prior cHL-directed treatment
- Prior chemotherapy, RT or allogeneic stem cell/solid organ transplant
- Prior or concurrent disease precluding protocol treatment (for details see section 4.2)
- Pregnancy or breastfeeding
- Non-compliance
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2028
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06916416
Start Date
June 1 2025
End Date
June 1 2028
Last Update
April 8 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.